ClinicalTrials.Veeva

Menu

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Beth Israel Lahey Health logo

Beth Israel Lahey Health

Status and phase

Completed
Phase 4

Conditions

Prostate Disease
Benign Prostatic Hyperplasia
Prostate Adenocarcinoma
Anxiety and Fear
Pain
Prostate Cancer
Malignancy

Treatments

Drug: Self-Administered Nitrous Oxide
Other: Oxygen

Study type

Interventional

Funder types

Other

Identifiers

NCT05803096
2021P-000715

Details and patient eligibility

About

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.

Full description

Nitrous oxide is a well-tolerated inhaled anesthetic that has been used for decades in pediatric and adult populations and is largely viewed as effective and safe. In addition to analgesic effect, nitrous oxide also produces a dissociative euphoria and amnesia that could potentially improve patients' anxiety and experience of cancer care. When used as a single agent at concentrations ≤50%, the American Society of Anesthesiologists (ASA) classifies nitrous oxide as Minimal Sedation, producing a state in which a patient responds normally to verbal commands, maintains airway reflexes, and spontaneous ventilation. Over the past several decades nitrous oxide has become less common due to concerns of nitrous oxide environmental exposure to the care team. There are now Federal Drug Administration (FDA)-approved systems that allow patient self-administered nitrous oxide (SANO), and importantly, include a scavenger system to eliminate exhaled environmental nitrous oxide. These systems are rapidly being adopted throughout the United States in Urology practices, but to date, there have been no studies evaluating patient outcomes and possible risks with the adjunct use of SANO. This study is a prospective, randomized, controlled trial to assess patient perceived pain and anxiety related to prostate needle biopsy with or without SANO, and the frequency of complications associated with SANO. A secondary aim will be to demonstrate that the SANO at the time of prostate biopsy does not significantly increase burden on Urologist productivity, nor increase the difficulty of operator ease in performing the prostate needle biopsy.

Enrollment

143 patients

Sex

Male

Ages

18 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Biological male
  • Aged 18 to 85 years
  • Scheduled for clinically-indicated prostate needle biopsy
  • Suitable for nitrous oxide/oxygen with willingness to be randomized to inhaled SANO or inhaled oxygen during the procedure
  • Access to an email and computer

Exclusion criteria

  • Perioral facial hair impeding good mask seal

  • Learning disabilities and/or inability to cognitively complete survey questions

  • Taken a pre-procedure benzodiazepine or narcotic.

  • Has any of the following medical conditions:

    1. Inner ear, bariatric or eye surgery within the last 2 weeks,
    2. Current emphysematous blebs,
    3. Severe B-12 deficiency.
    4. Bleomycin chemotherapy within the past year.
    5. Class III or higher heart failure.
    6. Undergoing novel therapy for prostate cancer

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

143 participants in 2 patient groups, including a placebo group

Self-Administered Nitrous Oxide
Active Comparator group
Description:
Patients will receive SANO in addition to periprostatic bupivacaine nerve block for the duration of prostate biopsy. After the Urologist describes the procedure, the SANO group will have nitrous oxide turned on to 30%, ensuring that the patient is relaxed but still conversant through the procedure. The nitrous will be adjust up or down based on the patient's response to the question "are you feeling the nitrous" and "are you happy at this level". The range will be between 25 - 45%. At the end of the procedure, the SANO group will be turned down to 0% nitrous oxide, and 100% oxygen will be administered through the mask for an additional 2-3 minutes as the patient is cleaned up and repositioned to the supine position.
Treatment:
Drug: Self-Administered Nitrous Oxide
Oxygen
Placebo Comparator group
Description:
Patients will receive 100% oxygen at 10 Liters/minute for the duration of prostate biopsy.
Treatment:
Other: Oxygen

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems